6533b7dbfe1ef96bd126ff7c
RESEARCH PRODUCT
Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk
G DumoulinElisabeth MonnetXavier GuillotF. AubinDaniel WendlingMaxime DesmaretsMaxime DesmaretsJerome GillardB. AugeEric ToussirotCaroline LaheurteCaroline LaheurteOlivier Messicasubject
LeptinMalemedicine.medical_specialtyAdipokineIntra-Abdominal FatGastroenterologyBody Mass Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisSex Factors0302 clinical medicineInsulin resistanceAdipokinesRheumatologyInternal medicinemedicineHumansInsulinPsoriasisResistinPharmacology (medical)030203 arthritis & rheumatologyAdiponectinbusiness.industryArthritis PsoriaticAge FactorsMiddle Agedmedicine.diseaseObesityHeart Disease Risk FactorsCase-Control StudiesObesity AbdominalMultivariate AnalysisBody CompositionFemaleResistinAndroid fat distributionInsulin ResistanceMetabolic syndromebusinessRetinol-Binding Proteins Plasmadescription
Abstract Background Fat mass distribution, especially in the abdominal visceral region, has been rarely evaluated in patients with PsA or psoriasis (PsO). Methods Patients with PsA and patients with PsO alone were evaluated and compared with control subjects (1:1 ratio in each patient group) matched for age, sex and BMI category. Body composition and fat distribution (android and visceral fat) were evaluated by DXA. Anthropometric measurements, disease activity and the systematic coronary risk evaluation (SCORE) cardiovascular risk were assessed. Metabolic parameters (insulin, homeostasis model assessment for insulin resistance), serum adipokines [total and high-molecular-weight adiponectin, leptin, resistin and retinol-binding protein-4 (RBP4)] were measured. Results Data for 52 patients with PsA and 52 patients with PsO and their respective paired controls were analysed. Android fat and visceral fat were found to be significantly higher in patients with PsO compared with their controls, while these measurements did not differ between patients with PsA and their controls. By multivariate analysis, after adjusting for age, sex and BMI, visceral fat was higher in PsO patients compared with PsA patients (P = 0.0004) and the whole group of controls (P = 0.0013). Insulin levels and HOMA-IR were increased in both PsA and PsO groups. High-molecular-weight/total adiponectin ratio was decreased in patients with PsO. RBP4 was significantly higher in both PsA and PsO patients. In patients with PsO, visceral fat strongly correlated with SCORE (r = 0.61). Conclusion Visceral fat accumulates more in PsO alone than in PsA. Visceral adiposity may be a more pressing concern in PsO relative to PsA. Trial registration The ADIPSO study (Évaluation du tissu ADIpeux et des adipokines dans le PSOriasis et le rhumatisme psoriasique et analyse de ses relations avec le risque cardiovasculaire) is a case–control study conducted in Besançon, France, and is registered on ClinicalTrials.gov under the number NCT02849795.
year | journal | country | edition | language |
---|---|---|---|---|
2020-08-16 | Rheumatology |